1. Home
  2. NVAX vs GSBD Comparison

NVAX vs GSBD Comparison

Compare NVAX & GSBD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • NVAX
  • GSBD
  • Stock Information
  • Founded
  • NVAX 1987
  • GSBD 2012
  • Country
  • NVAX United States
  • GSBD United States
  • Employees
  • NVAX N/A
  • GSBD N/A
  • Industry
  • NVAX Biotechnology: Biological Products (No Diagnostic Substances)
  • GSBD Finance: Consumer Services
  • Sector
  • NVAX Health Care
  • GSBD Finance
  • Exchange
  • NVAX Nasdaq
  • GSBD Nasdaq
  • Market Cap
  • NVAX 1.4B
  • GSBD 1.5B
  • IPO Year
  • NVAX 1995
  • GSBD N/A
  • Fundamental
  • Price
  • NVAX $8.38
  • GSBD $12.92
  • Analyst Decision
  • NVAX Buy
  • GSBD Hold
  • Analyst Count
  • NVAX 6
  • GSBD 3
  • Target Price
  • NVAX $17.83
  • GSBD $13.67
  • AVG Volume (30 Days)
  • NVAX 4.8M
  • GSBD 959.1K
  • Earning Date
  • NVAX 02-26-2025
  • GSBD 02-27-2025
  • Dividend Yield
  • NVAX N/A
  • GSBD 13.95%
  • EPS Growth
  • NVAX N/A
  • GSBD N/A
  • EPS
  • NVAX N/A
  • GSBD 0.67
  • Revenue
  • NVAX $885,193,000.00
  • GSBD $445,944,000.00
  • Revenue This Year
  • NVAX N/A
  • GSBD N/A
  • Revenue Next Year
  • NVAX N/A
  • GSBD N/A
  • P/E Ratio
  • NVAX N/A
  • GSBD $19.13
  • Revenue Growth
  • NVAX N/A
  • GSBD N/A
  • 52 Week Low
  • NVAX $3.60
  • GSBD $11.72
  • 52 Week High
  • NVAX $23.86
  • GSBD $15.94
  • Technical
  • Relative Strength Index (RSI)
  • NVAX 45.04
  • GSBD 59.93
  • Support Level
  • NVAX $8.30
  • GSBD $12.56
  • Resistance Level
  • NVAX $9.77
  • GSBD $12.97
  • Average True Range (ATR)
  • NVAX 0.56
  • GSBD 0.20
  • MACD
  • NVAX -0.06
  • GSBD 0.08
  • Stochastic Oscillator
  • NVAX 12.67
  • GSBD 83.73

About NVAX Novavax Inc.

Novavax Inc is a biotechnology company that develops vaccines. The company works in the clinical stage of development with a focus on delivering novel products that prevent a broad range of diseases. Novavax works together with its wholly owned Swedish subsidiary to produce vaccine candidates to respond to both known and emerging disease threats. The company believes its vaccine technology has the potential to be applied broadly to a wide variety of human infectious diseases. The Company manages its business as one operating segment, the development and commercialization of vaccines. The company generates maximum revenue from Europe.

About GSBD Goldman Sachs BDC Inc.

Goldman Sachs BDC Inc is a non-diversified, closed-end management investment company that elected to be regulated as a business development company focused on lending to middle-market companies. The investment objective is to generate current income and, to a lesser extent, capital appreciation primarily through direct originations of secured debt, including the first lien, unitranche and second lien debt, and unsecured debt. It invests primarily in U.S. middle-market companies such as banks and the public debt markets. The company's origination strategy focuses on leading the negotiation and structuring of the loans or securities in which it invests and holding the investments in its portfolio to maturity. It generates majority revenue in the form of interest income and dividend income.

Share on Social Networks: